🇺🇸 BioNTech SEBNTX
Get BioNTech SE filings on Telegram the moment they are published.
Follow BioNTech SE on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: The AHEAD-MERIT Phase 2/3 trial for BNT113 failed to meet its first dual primary endpoint of progression-free survival in metastatic HPV16-positive head and neck cancer.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest